Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase 3

Active, not recruiting

Conditions: T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Interventions: Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Asparaginase
Other: Laboratory Biomarker Analysis
Drug: Daunorubicin Hydrochloride
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Leucovorin Calcium
Drug: Dexamethasone
Drug: Pegaspargase
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Drug: Nelarabine
Drug: Vincristine Sulfate
Radiation: Radiation Therapy
Drug: Thioguanine

First Posted Date: 2006-12-05

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1895

Registration Number: NCT00408005

Locations: 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 212 locations

Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: methylprednisolone
Drug: prednisolone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2006-11-17

Last Posted Date: 2024-11-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 800

Registration Number: NCT00400946

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦
Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada

and more 5 locations

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: leucovorin calcium
Drug: liposomal cytarabine
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate

First Posted Date: 2006-10-26

Last Posted Date: 2018-06-06

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 34

Registration Number: NCT00392834

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States

and more 10 locations

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Phase 2

Completed

Conditions: BCR-ABL1 Fusion Protein Expression
Recurrent Acute Lymphoblastic Leukemia
t(9;22)
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Methotrexate
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2006-10-20

Last Posted Date: 2024-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT00390793

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia

Interventions: Drug: 5-Azacytidine
Drug: Ara-C
Drug: Valproic Acid (VPA)

First Posted Date: 2006-09-29

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00382590

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: L1 Childhood Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: vincristine sulfate
Drug: prednisone
Drug: doxorubicin hydrochloride
Drug: pegaspargase
Drug: cytarabine
Drug: methotrexate
Drug: dexamethasone
Drug: etoposide
Drug: cyclophosphamide
Drug: leucovorin calcium
Biological: filgrastim
Drug: asparaginase
Drug: mercaptopurine

First Posted Date: 2006-09-28

Last Posted Date: 2024-03-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 275

Registration Number: NCT00381680

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States

and more 170 locations

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: clofarabine
Drug: cytarabine
Drug: methotrexate
Other: laboratory biomarker analysis

First Posted Date: 2006-09-07

Last Posted Date: 2017-06-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 74

Registration Number: NCT00372619

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

and more 76 locations

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: gemtuzumab ozogamicin
Drug: mitoxantrone hydrochloride

First Posted Date: 2006-09-07

Last Posted Date: 2021-03-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1070

Registration Number: NCT00372593

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 195 locations

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 3

Completed

Conditions: Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
Childhood Acute Basophilic Leukemia
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Eosinophilic Leukemia
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myelomonocytic Leukemia (M4)
Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes

Interventions: Drug: asparaginase
Drug: daunorubicin hydrochloride
Drug: cytarabine
Drug: thioguanine
Drug: etoposide
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2022-01-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 205

Registration Number: NCT00369317

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University-Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 94 locations

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
X-linked Lymphoproliferative Disease (XLP)
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Familial Hemophagocytic Lymphohistiocytosis (FLH)
Viral-associated Hemophagocytic Syndrome (VAHS)
Hemophagocytic Lymphohistiocytosis (HLH)
Acute Lymphoblastic Leukemia
Non Hodgkins Lymphoma

Interventions: Drug: Ara-C
Drug: Cyclophosphamide
Biological: Campath-1H
Radiation: Total Body Irradiation
Procedure: Stem Cell Infusion

First Posted Date: 2006-08-24

Last Posted Date: 2020-01-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 46

Registration Number: NCT00368355

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hosptial, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy